Merck Reported Positive Trial Results for Remigromig

The pharmaceutical giant announced trial data for a new eye drug while noting potential safety concerns.

Updated on Sept. 24, 2026 in Biotech

Isometric editorial illustration showing a glass vial and lab equipment, representing pharmaceutical research and clinical trial outcomes. — Merck released clinical data for its eye drug remigromig, reporting non-inferiority to existing treatments while flagging concerns regarding ocular side effects. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to disclose all potential safety risks of new drugs?

Merck reported positive clinical trial results for its eye drug, remigromig, which achieved non-inferiority compared to Roche's Lucentis in the Brunello trial. However, the study also identified increased rates of eye bleeding and proliferative diabetic retinopathy among patients.

Why it matters

The trial data is crucial for Merck as the company works to diversify its portfolio and achieve a target of $70 billion in annual sales by the next decade. Assessing the safety profile of the drug remains a primary focus for investigators following the observed adverse events.

The Brunello trial measured visual acuity using injections every four weeks for one year, while the drug targets the Wnt signaling pathway.

The players

Merck

This global pharmaceutical company is headquartered in New Jersey and aims to reach $70 billion in annual sales next decade.

EyeBio

Merck acquired this biotechnology company in 2024 to gain control over its pipeline of ophthalmic drugs.

Roche

This multinational healthcare company manufactures the eye drug Lucentis, which served as the comparator in the Brunello trial.

The details

Participants in the remigromig group faced higher rates of treatment discontinuation alongside the reported ocular side effects. Merck acquired the drug, formerly known as Restoret, during its $1.3 billion takeover of EyeBio in 2024.

Merck acquired EyeBio and remigromig in 2024.
Merck announced results from the Brunello trial on September 24, 2026.
Full trial results will be presented at a medical meeting on October 10, 2026.

Corporate Finance
Sept. 22
Amgen Dazodalibep Trial Met Primary Endpoint
Biotech
Sept. 23
Ollin Biosciences Reported Positive JADE Study Results
Diabetes
Sept. 24
Surrozen Filed FDA Application for Diabetes Drug

The Tech Race

The development of remigromig represents a shift toward novel Wnt pathway targeting, which aims to replace or augment existing treatments for retinal conditions. Merck is currently positioning this therapy to compete in the high-stakes global market for advanced ocular pharmaceuticals.

Patients and healthcare providers should be aware that while remigromig demonstrated efficacy, the observed side effects of eye bleeding may influence future treatment protocols. The ongoing evaluation of this drug will determine its eventual availability and safety profile for those managing diabetic retinopathy.

The takeaway

Merck's pursuit of new ophthalmic treatments underscores the importance of weighing efficacy against safety risks in clinical development. Investors and patients should monitor the second pivotal trial for clearer insights into the long-term viability of the drug.